A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from birth
- Coverage achievable with two-week gap before early delivery
- Vaccination in third trimester still provides meaningful infant protection
Persuasive evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a thorough investigation carried out throughout England, examining data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month timeframe, providing robust and representative evidence of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research offers healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across diverse populations and circumstances.
The results reveal a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction emphasises the vaccine’s critical role in reducing the risk of serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology captured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when administered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to breathe and feed properly. Parents frequently observe their babies struggling visibly, their chests rising whilst they work to get sufficient oxygen into their compromised lungs. Whilst most infants improve through clinical support, a small but significant number die from respiratory syncytial virus complications yearly, making prevention through vaccination a vital health service imperative for defending the most vulnerable and youngest members of society.
- RSV triggers lung inflammation, causing severe breathing difficulties in infants
- Nearly 50% of newborns contract the virus in their first few months of life
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants need serious hospital treatment for RSV each year
- Few babies succumb to RSV related complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured pregnant women that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to connect with pregnant women
- Geographic variations in vaccination coverage levels in different parts of England demand focused enhancement
- Local healthcare systems tailoring initiatives to align with local requirements and situations
Real-world impact and parental perspectives
The vaccine’s outstanding effectiveness provides concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this protective measure, the 80% drop in admissions represents thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns gasping for air or difficulty feeding, symptoms that define critical RSV illness. The vaccine has markedly changed the picture of neonatal lung health, giving expectant mothers a proactive tool to shield their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection resulted in severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s support of the jab emphasises the profound consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers in their third trimester, converting what was once an unavoidable seasonal threat into a manageable risk.